Recordati Buyout Financing Reaches Second Settlement as Sofinnova Closes €725 Million Biotech Fund

Recordati Buyout Financing Reaches Second Settlement as Sofinnova Closes €725 Million Biotech Fund

Mon, November 16, 2026

A multibillion-euro financing package for the acquisition of Italian pharmaceutical company Recordati is advancing to its second settlement, highlighting the scale of leveraged buyout funding available for major European healthcare transactions even as credit markets remain selective.

The transaction, backed by a consortium involving CVC and GBL, includes €6.05 billion in senior secured bridge facilities, an €850 million revolving and term facility, an €11 billion guarantee facility connected with tender-offer cash confirmation letters, and €1.53 billion of privately placed pay-if-you-want payment-in-kind toggle notes. According to Latham & Watkins, which advised on the financing, the facilities are being used to fund consideration payable at the second settlement of the tender offer on November 17, 2026.

Recordati Deal Tests European Buyout Financing

The structure illustrates how sponsors and banks are combining bridge loans, revolving facilities, guarantees and hybrid debt to fund large acquisitions. The use of several financing instruments gives the consortium flexibility across the tender-offer process while distributing risk among bank lenders, bond investors and private-credit participants.

For investors, the financing is significant because it provides a current read on the capacity of European credit markets to absorb large healthcare buyouts. It also demonstrates the importance of financing certainty in tender offers, where acquisition consideration must be supported before shareholders receive payment.

The latest development is the second settlement funding stage rather than a new proposal for Recordati. Earlier financing commitments remain relevant as background, but the current focus is the deployment of the package to support the next payment stage of the tender offer.

Sofinnova Raises €725 Million for European Biotech

In a separate development, life-sciences investment firm Sofinnova Partners has closed a €725 million fund aimed at supporting the expansion of European biotechnology, according to Reuters.

The fundraising gives Sofinnova additional capital for investments across a European biotech market that continues to attract institutional interest despite difficult financing conditions for many early-stage companies. Fund closings provide investors with committed capital for future transactions, but they should not be confused with capital already deployed into individual companies.

The fund is expected to compete for opportunities across a sector where drug-development companies often require several rounds of financing before reaching clinical, regulatory or commercial milestones. For portfolio companies, backing from a specialist investor can provide both capital and access to a broader network of pharmaceutical, technology and financial partners.

Together, the Recordati financing and Sofinnova fund close show two different channels for healthcare capital allocation: structured acquisition financing for an established pharmaceutical company and newly committed investment capital for the European biotechnology pipeline. Investors will be watching the completion timetable for the Recordati tender offer and the pace at which Sofinnova deploys its new fund.